Replies to post #55393 on Ariad Pharmaceuticals Inc fka ARIA

[AmpleKind]

There is ZERO chance of front line.

AND

And without first line, Ariad is doomed to remain a standalone biotech.

Dognatic and totally unfounded assertions!
As the only drug that eliminates mutations, and gives patients
some hope of getting off drugs altogether, there's going to be
a lot of work (In the clinic and labs) to make it safe and maximally
beneficial to CML patients.

If I had CML, I would go for Iclusig first, especially if my doctor
was Dr.Cortez. Note that that sort of clinical excellence will at some
point become standard protocol, and continued experience in the
clinic will make Pona a much safer and desirable first line option.

bio.rese emphasizes all the risks, but ignores the benefits,
and the high probability of improved clinical outcomes as
oncologists gain experience with the drug.

That may resonate on boards, but not in medical situations
where patient benefit is paramount.

[piece o mind]

2da's posts are informative and realistic in terms of investing decisions and the company's future. stubborn as he may well be, there is no way the harv, or any of his cronies, or denner, doesn't see the situation of the company as 2da does. would hate to think the harv has lost his sense of reality with the situation (aka. one flew over the cuckoos nest). there have been some minor positive news about ariads progress that have come out these past few months, that can also help benefit a large bios portfolio if successful. those positives plus Mn can also lead to a more decent bid for a BO within the next year. with that in mind (and hoping the harv does have some sense of reality left), i continue to hold for the greater good that these drugs get the ability to mature through a well financed pharmaceutical company, which in turn will benefit the longs who have endured.